Statistics on Chinese APIs are misleading, according to the US-China Business Council (USCBC) — a private, nonpartisan, nonprofit organization of more than 270 American companies that do business with China. “Congressional testimonies and publications often cite that ’80 percent of APIs used in US drugs are sourced from China. However, this statistic misrepresents findings from (FDA) reports on the location of API manufacturing facilities, not their production,” USCBC reported. “The FDA has since acknowledged it “[does] not know whether Chinese facilities are actually producing APIs, how much they are producing, or where the APIs [are] distributed.”